Juventas Completed Around $14 Million In Series A+ Financing

Juventas just completed around 14 million dollars in Series A+ financing, this round of financing was led by CASI and followed by Ruifu Medical Venture. The funds will be used to increase R&D investment, clinical research and GMP production plant construction. Before this round of investment, Juventas has already raised more than 23 million dollars of financing.

Juventas was founded in 2018, it’s a pharmaceutical company specializing in the development of new immune cell therapeutics, dedicated to providing high quality and safe immune cell cures for cancer patients worldwide. At present, the company's first clinical application for cell therapy CNCT19 has been accepted by the State Drug Administration. Follow-up products will continue to be improved, providing effective treatment for malignant hematological tumors such as leukemia and lymphoma as well as malignant solid tumors. Right now, Juventas is building its new GMP immune cell drug production base.

CASI is a U.S. NASDAQ-listed biopharmaceutical company with a platform to develop and accelerate the launch of pharmaceutical products and innovative therapeutics in China, U.S. and throughout the world.

Ruifu Medical Venture it's a Chinese venture capital that focuses in the fields of medicines and health care.